.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB60_PeginterferonAlfa2bCombi.PeginterferonAlfa2bCombi .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB60_PeginterferonAlfa2bCombi.PeginterferonAlfa2bCombi| name: | PeginterferonAlfa2bCombinations |
| ATC code: | L03AB60 | route: | subcutaneous |
| n-compartments | 1 |
Peginterferon alfa-2b, in combination with ribavirin or other agents, is a pegylated form of interferon used primarily in the treatment of chronic hepatitis C and sometimes hepatitis B. It acts as an immunomodulator and antiviral agent. Although it was previously a standard of care, direct-acting antivirals have largely replaced it in many markets, but it is still approved in some regions.
Pharmacokinetic parameters reported in adult patients, mixed sex, with chronic hepatitis C infection treated subcutaneously with peginterferon alfa-2b (combinations with ribavirin).
Xu, C, et al., & Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. European journal of clinical pharmacology 69(12) 2045–2054. DOI:10.1007/s00228-013-1574-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23975236
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650